BioWisdom Announces Renewal of Collaboration Involving OmniViz's Intelligent Visual Analytics Technology

CAMBRIDGE, UNITED KINGDOM--(Marketwire - March 06, 2008) - BioWisdom Ltd (BioWisdom), a market leader in delivering healthcare intelligence to the pharmaceutical industry, today announced that Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) has extended its Collaboration Agreement with OmniViz, Inc., extending J&JPRD´s license rights to OmniViz software for information visualization and data mining.

"We are delighted with J&JPRD´s decision to continue its relationship with OmniViz" said Michael Stapleton, BioWisdom´s CBO. "As our investment in the creation of truly ontology powered applications like OmniViz grows, so does the importance of our strategic collaborators with real world use cases and validation."

OmniViz visual intelligence software is a complete solution for all data visualization, uniquely supporting the analysis of text, numeric and categorical information.

Notes to Editors

ABOUT BIOWISDOM

BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the formatting, search, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development.

Contacts:
BioWisdom Ltd
Gordon Baxter
CEO
+44 (0)1223 874800

BioWisdom Ltd
Julie Barnes
CSO
+44 (0)1223 874800

BioWisdom Ltd
Jason Marth
Director of Sales
+44 (0)1223 874800
Email: info@biowisdom.com
Website: www.biowisdom.com

The Hogarth Partnership
Melanie Toyne-Sewell
+44 (0)207 357 9477
Email: mtoyne-sewell@hogarthpr.co.uk

The Hogarth Partnership
Sarah Richardson
+44 (0)207 357 9477
Email: srichardson@hogarthpr.co.uk

The announcement was distributed by Hugin.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.